Cargando…

A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients

Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Huanhuan, Zhou, Xiaoqian, Jin, Hui, Li, Xiang, Zheng, Miao, Ming, Xu, Wang, Ruitao, Liu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834155/
https://www.ncbi.nlm.nih.gov/pubmed/27127507
http://dx.doi.org/10.1155/2016/1878194
_version_ 1782427449814941696
author Yan, Huanhuan
Zhou, Xiaoqian
Jin, Hui
Li, Xiang
Zheng, Miao
Ming, Xu
Wang, Ruitao
Liu, Jun
author_facet Yan, Huanhuan
Zhou, Xiaoqian
Jin, Hui
Li, Xiang
Zheng, Miao
Ming, Xu
Wang, Ruitao
Liu, Jun
author_sort Yan, Huanhuan
collection PubMed
description Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective study of 543 patients with PTC undergoing hemithyroidectomy or total thyroidectomy with routine central lymph node dissection (CLND) was analyzed. Clinicopathologic risk factors for CLNM were studied using univariate and multivariate analysis by SPSS 22.0 software. Results. The incidence of CLNMs in PTC patients was 38.1% (207/543). In the multivariate analysis, male gender (p < 0.001, OR: 1.984), age <45 years (p < 0.001, OR: 1.934), bilaterality (p = 0.006, OR: 1.585), tumor size ≥0.25 cm (p = 0.001, OR: 7.655), and external extension (p = 0.001, OR: 7.579) were independent risk factors of CLNMs. Furthermore, in PTC patients with tumor size <0.25 cm, all 7 males and 21 patients with unilaterality were not found to have CLNMs. Conclusions. CLNMs are prevalent in the PTC patients with the following risk factors: male gender, age <45 years, bilaterality, tumor size ≥0.25 cm, and external extension. PTC patients with tumor size <0.25 cm, male patients, and patients with unilateral lesion could be considered safe from CLNMs.
format Online
Article
Text
id pubmed-4834155
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48341552016-04-28 A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients Yan, Huanhuan Zhou, Xiaoqian Jin, Hui Li, Xiang Zheng, Miao Ming, Xu Wang, Ruitao Liu, Jun Int J Endocrinol Research Article Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective study of 543 patients with PTC undergoing hemithyroidectomy or total thyroidectomy with routine central lymph node dissection (CLND) was analyzed. Clinicopathologic risk factors for CLNM were studied using univariate and multivariate analysis by SPSS 22.0 software. Results. The incidence of CLNMs in PTC patients was 38.1% (207/543). In the multivariate analysis, male gender (p < 0.001, OR: 1.984), age <45 years (p < 0.001, OR: 1.934), bilaterality (p = 0.006, OR: 1.585), tumor size ≥0.25 cm (p = 0.001, OR: 7.655), and external extension (p = 0.001, OR: 7.579) were independent risk factors of CLNMs. Furthermore, in PTC patients with tumor size <0.25 cm, all 7 males and 21 patients with unilaterality were not found to have CLNMs. Conclusions. CLNMs are prevalent in the PTC patients with the following risk factors: male gender, age <45 years, bilaterality, tumor size ≥0.25 cm, and external extension. PTC patients with tumor size <0.25 cm, male patients, and patients with unilateral lesion could be considered safe from CLNMs. Hindawi Publishing Corporation 2016 2016-04-03 /pmc/articles/PMC4834155/ /pubmed/27127507 http://dx.doi.org/10.1155/2016/1878194 Text en Copyright © 2016 Huanhuan Yan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yan, Huanhuan
Zhou, Xiaoqian
Jin, Hui
Li, Xiang
Zheng, Miao
Ming, Xu
Wang, Ruitao
Liu, Jun
A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title_full A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title_fullStr A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title_full_unstemmed A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title_short A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
title_sort study on central lymph node metastasis in 543 cn0 papillary thyroid carcinoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834155/
https://www.ncbi.nlm.nih.gov/pubmed/27127507
http://dx.doi.org/10.1155/2016/1878194
work_keys_str_mv AT yanhuanhuan astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT zhouxiaoqian astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT jinhui astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT lixiang astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT zhengmiao astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT mingxu astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT wangruitao astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT liujun astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT yanhuanhuan studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT zhouxiaoqian studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT jinhui studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT lixiang studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT zhengmiao studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT mingxu studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT wangruitao studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients
AT liujun studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients